
Vaccinex VCNX
Annual report 2024
added 04-15-2025
Vaccinex Cost of Revenue 2011-2025 | VCNX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Vaccinex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2 K | 199 K | 1.03 M | 160 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 M | 2 K | 348 K |
Quarterly Cost of Revenue Vaccinex
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2 K | - | - | - | 8 K | 16 K | 175 K | - | 246 K | 246 K | 240 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 246 K | 2 K | 133 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
358 M | $ 25.27 | -2.43 % | $ 1.22 B | ||
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Aclaris Therapeutics
ACRS
|
2.79 M | $ 3.26 | -3.12 % | $ 252 M | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | ||
|
Kamada Ltd.
KMDA
|
73.3 M | $ 7.03 | 0.14 % | $ 260 M | ||
|
Ascendis Pharma A/S
ASND
|
3.52 M | $ 220.27 | 4.81 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
737 K | $ 0.91 | -5.01 % | $ 18.7 M | ||
|
AstraZeneca PLC
AZN
|
12.4 B | $ 89.78 | -0.57 % | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
Anika Therapeutics
ANIK
|
63.6 M | $ 9.57 | 0.84 % | $ 140 M | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
20.6 M | $ 2.34 | 2.59 % | $ 14.7 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
4 K | - | -19.68 % | $ 18.4 M | ||
|
Aptorum Group Limited
APM
|
421 K | $ 1.29 | -3.01 % | $ 7.03 M | ||
|
Baudax Bio
BXRX
|
7.01 M | - | 0.59 % | $ 63 K | ||
|
Catalyst Biosciences
CBIO
|
4.64 M | $ 14.01 | -8.49 % | $ 922 M | ||
|
ChromaDex Corporation
CDXC
|
38 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
841 M | $ 566.18 | -2.56 % | $ 42.9 B | ||
|
Cerus Corporation
CERS
|
33.4 M | $ 2.16 | 0.47 % | $ 399 M | ||
|
Caladrius Biosciences
CLBS
|
31.1 M | - | -16.75 % | $ 25.8 M | ||
|
Biogen
BIIB
|
2.31 B | $ 174.42 | 1.11 % | $ 25.4 B | ||
|
BioVie
BIVI
|
312 K | $ 1.42 | -5.96 % | $ 2.1 M | ||
|
Celldex Therapeutics
CLDX
|
200 K | $ 27.36 | -2.09 % | $ 1.76 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.73 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 11.54 | 0.87 % | $ 746 M |